News | February 07, 2026
Novo Nordisk threatens legal action over Hims & Hers ‘knockoff’ semaglutide pill
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments
Subscribe To Our Newsletter & Stay Updated
